MX2017006422A - Composiciones para tratar dolor agudo, post-operatorio, o cronico y metodos para usar las mismas. - Google Patents

Composiciones para tratar dolor agudo, post-operatorio, o cronico y metodos para usar las mismas.

Info

Publication number
MX2017006422A
MX2017006422A MX2017006422A MX2017006422A MX2017006422A MX 2017006422 A MX2017006422 A MX 2017006422A MX 2017006422 A MX2017006422 A MX 2017006422A MX 2017006422 A MX2017006422 A MX 2017006422A MX 2017006422 A MX2017006422 A MX 2017006422A
Authority
MX
Mexico
Prior art keywords
compositions
post
methods
operative
treating acute
Prior art date
Application number
MX2017006422A
Other languages
English (en)
Inventor
Chen Xi
M Criscione Jason
m reynolds Francis
DAI Haining
B Werth Nicholas
a armstrong Patrick
Samuel Langer Robert
Original Assignee
Pixarbio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pixarbio Corp filed Critical Pixarbio Corp
Publication of MX2017006422A publication Critical patent/MX2017006422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente composiciones para tratar dolor agudo, crónico, o post-operatorio en un sujeto, las composiciones que comprenden un agente anti-convulsivo y un portador biodegradable, en donde el agente se incorpora dentro del portador biodegradable. También se describen en la presente métodos para tratar dolor en un sujeto y kits para producir composiciones para tratar dolor agudo, crónico o post-operatorio en un sujeto.
MX2017006422A 2014-11-18 2015-11-11 Composiciones para tratar dolor agudo, post-operatorio, o cronico y metodos para usar las mismas. MX2017006422A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081162P 2014-11-18 2014-11-18
PCT/US2015/060093 WO2016081236A1 (en) 2014-11-18 2015-11-11 Compositions for treating acute, post-operative, or chronic pain and methods of using the same

Publications (1)

Publication Number Publication Date
MX2017006422A true MX2017006422A (es) 2017-09-12

Family

ID=55960737

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006388A MX2017006388A (es) 2014-11-18 2015-02-23 Composiciones para tratar dolor agudo, postoperatorio o cronico y metodo y uso de las mismas.
MX2017006422A MX2017006422A (es) 2014-11-18 2015-11-11 Composiciones para tratar dolor agudo, post-operatorio, o cronico y metodos para usar las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006388A MX2017006388A (es) 2014-11-18 2015-02-23 Composiciones para tratar dolor agudo, postoperatorio o cronico y metodo y uso de las mismas.

Country Status (10)

Country Link
US (3) US20160136179A1 (es)
EP (2) EP3220955A4 (es)
JP (2) JP2017537881A (es)
CN (2) CN107206097A (es)
AU (2) AU2015350554A1 (es)
BR (2) BR112017010430A2 (es)
CA (2) CA2967287A1 (es)
IL (2) IL251881A0 (es)
MX (2) MX2017006388A (es)
WO (3) WO2016081022A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147147A1 (en) * 2016-02-23 2017-08-31 PixarBio Corporation Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same
CN106902095B (zh) * 2017-03-08 2021-11-05 东北林业大学 一种集化疗与免疫疗法为一体的载黄芩苷纳米制剂及其制备方法
US11571429B2 (en) * 2017-05-23 2023-02-07 Upexmed Co. Ltd. Method and compounds for treating peripheral neuropathy
US20180338929A1 (en) * 2017-05-23 2018-11-29 Soon Kap Hahn Method and Compounds for Treating Peripheral Neuropathy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
US5948384A (en) * 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
EP0778768B1 (en) * 1995-06-09 2004-05-26 Euroceltique S.A. Formulations and methods for providing prolonged local anesthesia
EP1575562B1 (en) * 2002-11-26 2016-10-05 Seacoast Neurosciene, Inc. Buoyant polymer particles delivering therapeutic agents
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP1835913A2 (en) * 2004-12-06 2007-09-26 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
US20100204178A1 (en) * 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20080069857A1 (en) * 2006-04-12 2008-03-20 Yoon Yeo Compositions And Methods For Inhibiting Adhesions
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
WO2007133807A2 (en) * 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP2265287B1 (en) * 2008-03-04 2018-09-05 Teva Pharmaceuticals International GmbH Methods of treating chronic pain
WO2010001932A1 (ja) * 2008-07-01 2010-01-07 日東電工株式会社 表面被覆微粒子の医薬組成物
CN102348468B (zh) * 2009-07-31 2014-11-05 西安力邦医药科技有限责任公司 微球药物载体、其制备方法、组合物及应用
WO2011011978A1 (zh) * 2009-07-31 2011-02-03 西安力邦医药科技有限责任公司 微球药物载体、其制备方法、组合物及应用
US9549901B2 (en) * 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
WO2012075451A2 (en) * 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
PL3415139T3 (pl) * 2011-06-14 2022-07-11 Neurelis, Inc. Podawanie benzodiazepiny
WO2013042125A2 (en) * 2011-09-21 2013-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nano delivery systems
EP2925327B1 (en) * 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
CN103610664B (zh) * 2013-12-11 2015-09-16 中国药科大学 一种制备卡马西平聚乳酸-羟基乙酸共聚物微胶囊的方法

Also Published As

Publication number Publication date
EP3220955A1 (en) 2017-09-27
WO2016081022A1 (en) 2016-05-26
MX2017006388A (es) 2017-08-21
AU2015350554A1 (en) 2017-04-27
JP2017533943A (ja) 2017-11-16
BR112017010428A2 (pt) 2017-12-26
CN107405351A (zh) 2017-11-28
CA2967335A1 (en) 2016-05-26
BR112017010430A2 (pt) 2017-12-26
IL251880A0 (en) 2017-06-29
EP3220917A1 (en) 2017-09-27
IL251881A0 (en) 2017-06-29
US20160136179A1 (en) 2016-05-19
JP2017537881A (ja) 2017-12-21
US20170224621A1 (en) 2017-08-10
US20160317446A1 (en) 2016-11-03
WO2016081236A1 (en) 2016-05-26
CN107206097A (zh) 2017-09-26
EP3220917A4 (en) 2018-07-25
EP3220955A4 (en) 2018-07-25
AU2015350347A1 (en) 2017-05-04
WO2016081445A1 (en) 2016-05-26
CA2967287A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
GB2538178A (en) Viscosifier polymer for treatment of a subterranean formation
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017004579A (es) Estructuras fibrosas solubles y metodos para fabricarlas.
TW201614068A (en) Fucosidase from bacteroides and methods using the same
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
MX2017007645A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
AU2016263598A8 (en) Methods and kits for treating depression
EP3252019A4 (en) Method for treating wastewater, and activator for treating wastewater
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2017008414A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
GB2569488A (en) PD-1 specific aptamers
MX2017006422A (es) Composiciones para tratar dolor agudo, post-operatorio, o cronico y metodos para usar las mismas.
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
MX2015013021A (es) 5-bromo-indirrubinas.
MX2017009180A (es) Biomateriales de nanocelulosa sintetizada bacterialmente y de fases múltiples, y método para producirlos.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2017001985A (es) Composiciones para inhibir la inflamacion en un sujeto con lesion de medula espinal y metodos de uso de las mismas.